If you couldn’t make it to the American Heart Association’s (AHA) Scientific Sessions in Chicago this month, Cleveland Clinic Cardiovascular Medicine Chair Steven Nissen, MD, has got you covered. He recaps in the video below several of the most important presentations and other developments.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
He starts by sharing the many things to like about the new 2018 guideline on blood cholesterol management from the AHA and other societies — along with the one criticism he has of it. Then he explains why three studies presented at the meeting — the huge VITAL trial of vitamin D and omega-3, the controversial REDUCE-IT study of icosapent ethyl for hypertriglyceridemia, and a striking phase 2 study of a novel therapy for lowering lipoprotein(a) — are well worth knowing about.
Further acute testing not needed if ECG and high-sensitivity troponin are negative
Scott Cameron, MD, PhD, also brings wide-ranging research interests to bear
Pioneering U.K. vascular surgeon joins Cleveland Clinic
AHA statement is first comprehensive document on perioperative stroke reduction
Recognition reflects prioritization of long-term patient outcomes
Recommendations help distinguish exercise-induced remodeling from pathology
JACC review highlights factors unique to women, ways to tailor management
Pushing the envelope in ablation of atrial fibrillation, ventricular tachycardia